Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annu... (ychiatric problems including clinical de...)

HOME >> MEDICINE >> TECHNOLOGY

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting

Date:5/15/2008

ychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON and/or INTRON A be discontinued, and the patient be carefully followed with psychiatric intervention, as appropriate. Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. Dental and periodontal disorders have been reported in patients receiving PEGINTRON or INTRON A in combination with REBETOL therapy.

Please see important full U.S. prescribing information and the Medication Guide for PEGINTRON at http://www.schering-plough.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, inc
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
2. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
3. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
4. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
7. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
8. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
9. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research

Post Your Comments:

(Date:5/23/2013)... , May 23, 2013 Israel Brain ... 2013 , Israel,s 1 st ... 14 th -15 th in Tel Aviv ... innovative city in the world by the Wall Street ... BrainTech Israel 2013 will showcase the latest breakthroughs in ...

(Date:5/23/2013)... , May 23, 2013 EarlySense, ... today that the prize for ,Best Novel Idea, at ... Medical Emergency Teams International Conference, hosted this year in ... awarded to a clinical research team studying the impact ... Hospital in Los Angeles . The ...

(Date:5/23/2013)... May 23, 2013 SynCardia Systems, Inc. ( ... FDA, Health Canada and CE ( Europe ... Glasgow Science Centre in Scotland , ... the SynCardia temporary Total Artificial Heart powered ... $3 million Bodyworks Exhibition, one of the most advanced ...

Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2 Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3 Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 2 Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 3 Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 4 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3

[0] Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference [0] Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference [0] Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition

... -- , - Cipralex Better Tolerated and at ... A/S announces new study data published today in ... (escitalopram) was superior to duloxetine in the acute,treatment ... was,at least as efficacious in long-term treatment(1). The ...

... for CPX-1 presented at ASCO confirm safety findings,and ... patients with,colorectal and other types of cancer., PRINCETON, ... positive safety and efficacy results from,its Phase I ... with heavily pre-treated, advanced solid,tumors. Results were presented ...

Cached Medicine Technology:Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 2 Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 3 Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 4 Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 5 Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer,Patients Treated with Therapy Based on Ratiometric Dosing 2 Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer,Patients Treated with Therapy Based on Ratiometric Dosing 3

Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer,Patients Treated with Therapy Based on Ratiometric Dosing

(Date:5/23/2013)... News) -- A modified version of the polio ... preliminary research suggests. Scientists at Duke Cancer ... PVSRIPO, uses an engineered form of the virus ... cancer cells. The therapy shows promise in the ... brain tumor, they said. "These early results ...

(Date:5/23/2013)... (May 23, 2013)Don,t doubt it when a woman harried ... remembering things. A new study published online in ... Society (NAMS), helps confirm with objective tests that what ... In the past, some studies showed that hot flashes ... studies showed that, even though there was a relationship ...

(Date:5/23/2013)... PA (PRWEB) May 23, 2013 ... Teaching Site, offering a comprehensive babysitting training course for ... program was developed by Indianapolis pediatrician Dr. Patricia Keener ... the care of an adult sitter who didn’t know ... well-rounded youth development program with a medical basis that ...

(Date:5/23/2013)... anti-cancer drug about to be tested in a clinical ... possible treatment for Alzheimer,s disease has failed to work ... Alzheimer,s patients, according to results of a study by ... professor of neuroscience affiliated with the Evelyn F. and ... Florida, emphasized the importance of verifying promising research results ...

(Date:5/23/2013)... The Rottenstein Law Group LLP, a New York-based nationwide ... Information Center at http://www.rotlaw.com/tylenol , dedicated to issues ... considering filing lawsuits. , The painkiller Tylenol (acetaminophen) ... according to a 2009 report from the U.S. Food ... FDA warned consumers against using more than the recommended ...

Breaking Medicine News(10 mins):Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2 Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2 Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3 Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2 Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3 Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2

[0] Modified Polio Virus May Help Fight Brain Tumors, Study Suggests [0] It's not your imagination: Memory gets muddled at menopause [0] Susquehanna Health Offers Safe Sitter Course for Tweens and Teens [0] Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study [0] Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center

... , ... new market research report is available in its catalogue: ... , http://www.reportlinker.com/p0166825/Antibiotic-Resistance-and-Antibiotic-Technologies-Global-Markets.html , Provide an in-depth ... antibiotics technologies , Offer an analysis of antibiotics resistance ...

... , WEDNESDAY, Dec. 2 (HealthDay News) -- In the ... patients in the United States have improved modestly, a ... more than 100,000 patients diagnosed with stage 4 non-small ... patient information was in the U.S. National Cancer Institute,s ...

... have metabolic syndrome, study finds , WEDNESDAY, Dec. 2 ... overweight college football players from being at higher risk ... disease, a new study suggests. , Researchers studied linemen ... obese. Of those, 42 percent had metabolic syndrome, a ...

... Va., Dec. 2 By now, most people have heard of ... the latest product on the market is now available at the ... at the amazingly low price of $14.99. , "This new product ... very low price, before making a bigger investment in a smokeless ...

... MONTREAL, Dec. 2 /PRNewswire/ - As part of its continued ... part of Pfizer, has pledged more than 40 million international ... Hemophilia (WFH). This is the largest donation ever made to ... impact to advance the WFH,s goals. , "This donation will ...

... , KNOXVILLE, Tenn., Dec. 2 TeamHealth ( www.teamhealth.com ... of Naples-based Emergency Physicians of Naples, LLC (EPN). Since ... Healthcare System to staff the emergency facilities at the Downtown ... EPN also provides the staffing for two stand-alone urgent care ...

Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets Gains Made in Lung Cancer Survival Oversized College Football Players May Face Heart Risks A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH TeamHealth Acquires Emergency Physicians of Naples, LLC

... Ultra Strep A Test is a color ... DLT uses antibody labeled color particles coated ... device. DLT allows greater sensitivity than the ... In the test procedure, a throat swab ...

... Fertell test is an easy to use, one ... reserve by means of determining the amount of ... sample. The test is performed two days after ... menstrual cycle) and is similar in design and ...

... The Cholestech GDX System delivers an unmatched combination ... ideal solution for assessing and monitoring a patient's ... demo, click here ., ,The CLIA-waived Cholestech ... A1C results in less than 5 minutes. The ...

... The Cholestech LDX System, using patented, ... plus glucose and ALT in only 5 ... new ALT test, you can get immediate ... measurement capabilities is not the only advantage ...

Medicine Products:

OSOM Ultra 25 Strep A Fertell Female Fertility Test Cholestech GDX System LDX Analyzer